KIDNEY TRANSPLANT REJECTION

This study tests whether adding the drug tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) can better control chronic active antibody-mediated rejection in kidney transplant recipients. About 50 participants with stable kidney function and certain biopsy res…

This study compares a new drug, frexalimab, to the standard drug tacrolimus in adults receiving their first kidney transplant. The goal is to see if frexalimab is better at preventing organ rejection and improving kidney function over 5 years. About 526 participants with low-to-m…

This study tests two drugs, carfilzomib and belatacept, along with standard steroids and immune-suppressing medicines, in 25 kidney transplant patients who have signs of rejection. The goal is to see if this combination is safe and can reduce harmful antibodies that attack the ne…

This study is testing whether a blood test (called Prospera) can accurately detect kidney transplant rejection, potentially replacing the need for a kidney biopsy. Researchers will compare the blood test results with standard biopsy analysis in 300 kidney transplant recipients. I…

This study is testing a new blood test called GraftAssureDx to see if it can detect kidney transplant rejection without needing a biopsy. About 125 adults who have had a kidney transplant will give blood and urine samples. Researchers will compare the test results to standard bio…

This study looks at whether changes in platelet function can signal kidney transplant rejection without needing a biopsy. Researchers will measure platelet activity in 60 adult kidney transplant patients before and after surgery, and compare results with standard biopsy findings.…

This study looks at whether a urine test (called CXCL10) can catch kidney transplant rejection that a standard blood test might miss. About 50 adults who need a kidney biopsy will provide urine samples. Researchers will compare the urine test results to the blood test and biopsy …